Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
WALTHAM, Mass., April 04, 2016 -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the appointment of Kavita Patel, M.D., M.S., F.A.C.P. to the Company’s Board of Directors. Dr. Patel has served as a Senior Fellow at The Brookings Institution, as well as a practicing physician at Johns Hopkins since January 2011.
“Dr. Patel brings extensive leadership experience in healthcare policy, healthcare research and patient advocacy to TESARO,” said Lonnie Moulder, CEO of TESARO. “Her expertise will be a valuable resource for the Company in the current healthcare environment as we execute on our mission of providing transformative therapies to people bravely facing cancer.”
Dr. Patel has more than fifteen years of healthcare leadership experience and clinical work, with an emphasis on bridging research, innovation, policy and advocacy. Prior to joining The Brookings Institution, Dr. Patel served as Director of Policy for the Office on Intergovernmental Affairs and Public Engagement at The White House from 2009 to 2010. Prior to that, she served as Deputy Staff Director for Health for Senator Edward M. Kennedy from 2007 to 2009. Currently, Dr. Patel serves as a member of the Board of Directors of SSM Healthcare and Dignity Healthcare, which are nonprofit integrated delivery systems and Community Catalyst, a national advocacy organization. She also serves as an advisory board member for the National Commission of Physician Payment Reform, the Robert Graham Center for Policy Studies in Family Medicine and Primary Care, and the Johns Hopkins Medicine Sibley Hospital Innovation Hub. Dr. Patel earned her Bachelor of Arts degree from the University of Texas at Austin, her M.D. from the University of Texas Health Science Center, and her M.S.H.S. from the University of California, Los Angeles.
About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com.
Investor/Media Contact: Jennifer Davis Sr. Director, Corporate Development & Investor Relations +1.781.325.1116 or [email protected]
